Clinical trial
Lipiodol Deposition in Hypervascular Tumors: Endhole vs. Pressure-modulated Delivery
NCT06204159 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Lipiodol Deposition in Hypervascular Tumors: Endhole vs. Pressure-modulated Delivery
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- February 1, 2024
- Completion date
- December 31, 2026
- Enrollment
- 12 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma, neuroendocrine tumors